Home  /  UPSM

UPSMTM: Why use Uncorrelated PANSS Score Matrix to analyze your PANSS data

  • Improve the specificity and precision of the established PANSS factors (symptom domains) in patients with schizophrenia
  • Understand the true magnitude of symptom change in schizophrenia clinical trials
  • Facilitate labelling and development of new treatments based on a better understanding of uncorrelated PANSS factor change
  • Use on existing PANSS data or on yet to be collected PANSS data.
  • Analyze completed studies to learn more from PANSS.
  • Common platform to compare completed studies and new ongoing studies.
  • Does not require any new training to medical personnel at sites.

Publications & Presentations:

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia (Schizophrenia Bulletin vol. 44 no. 3 pp. 593–602, 2018; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890480/pdf/sbx101.pdf

Download UPSMTM Table here

Improving the specificity and precision of PANSS factors: One approach to facilitate development of novel treatments in schizophrenia (Presentation to ISCTM, 2018-02-21; https://isctm.org/public_access/Feb2018/Presentations/S2-Hopkins.pdf

Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors (ICNS, December 1, 2017; http://innovationscns.com/panss-antipsychotic-drug-treatment/)

Characterization of specific and distinct patient types in clinical trials of acute schizophrenia using an uncorrelated PANSS score matrix transform (UPSM) https://doi.org/10.1016/j.psychres.2020.113569)
 
CLICK HERE FOR REPRINTS

For physical reprints of the publication(s) or UPSM table, please contact Seth Hopkins at Seth.Hopkins@sunovion.com

Background on UPSMTM

Positive and Negative Syndrome Scale (PANSS) total score is the standard primary efficacy measure in acute treatment studies of schizophrenia. However, the 30 PANSS items are, to varying degrees, inter-correlated. As a consequence of cross-item correlations, the apparent improvement in key clinical domains (eg, negative symptoms, disorganized thinking/behavior) may largely be attributable to improvement in a related clinical domain, such as positive symptoms, a problem often referred to as pseudospecificity. The uncorrelated PANSS score matrix minimizes the degree of correlation between each resulting transformed uncorrelated PANSS factor scores. The transformed uncorrelated factor scores correspond well with discrete symptom domains described by prior factor analyses, but between-factor change-scores correlations are markedly lower. The transformed uncorrelated factor scores provide a more robust understanding of the structure of symptom change in schizophrenia and suggest a means to evaluate the specificity of antipsychotic treatment effects.

How the Uncorrelated PANSS Score Matrix is used to transform PANSS data sets

The coefficients of score matrix (matrix is 30 rows of PANSS items x 7 columns of transformed PANSS scores) are used to transform individual PANSS assessments (ratings should be expressed either as change from baseline, or as absolute ratings) to reduce the PANSS items into 7 factor scores for each PANSS assessment. Each column of the score matrix represents a transformed factor. Each column contains coefficients to multiply the corresponding item scores of PANSS.

REQUEST INFORMATION